Clinical and Laboratory Findings in Patients with Potential SARS-CoV-2 Reinfection, May–July 2020

James T Lee¹, Elisabeth M Hesse³, Heather N Paulin¹, Deblina Datta¹, Lee S Katz¹, Amish Talwar¹, Gregory Chang¹, Romeo R. Galang¹, Jennifer L. Harcourt², Azaibi Tamin³, Natalie J. Thornburg³, Karen K. Wong¹, Valerie Stevens¹, Kaylee Kim¹, Suxiang Tong², Bin Zhou², Krista Queen², Jan Drobeniuc³, Jennifer M. Folster³, D. Joseph Sexton², Sumathi Ramachandran², Hannah Browne², John Iskander¹, Kiren Mitruka¹

¹ Health Systems Worker Safety Task Force, COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, USA
² Laboratory Task Force, COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, USA
³ Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, USA

Corresponding author:
James T Lee
yvr0@cdc.gov
Centers for Disease Control and Prevention
1600 Clifton Road.
ROYBAL BLDG 24 MS H24-4
Atlanta, GA 30329, USA
404.718.3654

Summary: In an investigation of cases of potential SARS-CoV-2 reinfection, including laboratory testing of recovered patients who developed recurrent COVID-19 symptoms with positive RT-PCR results for SARS-CoV-2, we did not confirm reinfection within the first three months after SARS-CoV-2 infection.
Abstract

Background
We investigated patients with potential SARS-CoV-2 reinfection in the United States during May–July 2020.

Methods
We conducted case finding for patients with potential SARS-CoV-2 reinfection through the Emerging Infections Network. Cases reported were screened for laboratory and clinical findings of potential reinfection followed by requests for medical records and laboratory specimens. Available medical records were abstracted to characterize patient demographics, comorbidities, clinical course, and laboratory test results. Submitted specimens underwent further testing, including RT-PCR, viral culture, whole genome sequencing, subgenomic RNA PCR, and testing for anti-SARS-CoV-2 total antibody.

Results
Among 73 potential reinfection patients with available records, 30 patients had recurrent COVID-19 symptoms explained by alternative diagnoses with concurrent SARS-CoV-2 positive RT-PCR, 24 patients remained asymptomatic after recovery but had recurrent or persistent RT-PCR, and 19 patients had recurrent COVID-19 symptoms with concurrent SARS-CoV-2 positive RT-PCR but no alternative diagnoses. These 19 patients had symptom recurrence a median of 57 days after initial symptom onset (interquartile range: 47 – 76). Six of these patients had paired specimens available for further testing, but none had laboratory findings confirming reinfections. Testing of an additional three patients with recurrent symptoms and alternative diagnoses also did not confirm reinfection.

Conclusions
We did not confirm SARS-CoV-2 reinfection within 90 days of the initial infection based on the clinical and laboratory characteristics of cases in this investigation. Our findings support current CDC guidance around quarantine and testing for patients who have recovered from COVID-19.

Keywords: SARS-CoV-2, COVID-19, coronavirus, re-infection, reinfection
INTRODUCTION

As of January 3rd, 2021, more than 83 million cases of coronavirus disease 2019 (COVID-19) have been confirmed worldwide, including 20 million cases in the United States [1]. For most diagnosed cases, the U.S. Centers for Disease Control and Prevention (CDC) recommends completing isolation at 10 days after symptom onset with resolution of fever for at least 24 hours [2]. This recommendation is based on the absence of replication-competent virus for 10 days following symptom onset in mild to moderately severe cases. Retesting is not recommended for 90 days among persons who remain asymptomatic after recovery because SARS-CoV-2 RNA can be detected in their upper respiratory specimens for up to 12 weeks [2-5]. Patients who do develop new symptoms within 90 days of recovery can be considered for retesting after investigation of alternative diagnoses. However, a better understanding of the duration and robustness of immunity to SARS-CoV-2 and the potential for reinfection would guide public health actions [6].

Reinfection has been documented among other species of human coronaviruses (HCoV), both experimentally [Callow] and in surveillance cohorts of community members [7, 8]. However, reinfection with SARS-associated coronavirus 1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV), two coronaviruses that can cause severe disease, has not been demonstrated, possibly related to the limited scope of these outbreaks [10, 11]. Recent case reports [12; 13] demonstrating phylogenetic differences in SARS-CoV-2 genomes isolated from initial and recurrent episodes of COVID-19 in the same patients raise concern for reinfection; however, questions remain about the frequency and timing of such cases.

During March–April 2020, several reports described cases of recurrent or prolonged SARS-CoV-2 RT-PCR positivity among individuals who had recovered from COVID-19 [14, 15]. An investigation in South Korea reported the absence of both viable virus and secondary transmission from investigated cases of recurrent SARS-CoV-2 RT-PCR positivity [4]. To better understand the clinical and public health implications of similar cases in the United States, in May 2020, CDC initiated an investigation of cases of potential reinfection. Here, we summarize the clinical characteristics and available laboratory findings of cases of potential reinfection reported to CDC by clinicians and public health officials.

METHODS

Case Finding

We conducted case finding through the Emerging Infections Network (EIN), a provider-based sentinel network of over 1100 actively practicing infectious diseases professionals mainly from North America. EIN is administered by the Infectious Disease Society of America under a CDC cooperative agreement to help identify and understand emerging infectious diseases or clinical manifestations [16]. On May 13, 2020, we published a post on the EIN listserv soliciting reports about potential cases of reinfection from members. We also publicized this EIN posting to state, tribal, territorial, and local health departments. Cases of interest included patients with laboratory-confirmed COVID-19 who had any of the following after clinical recovery:

1) Recurrent COVID-19 symptoms and reverse transcription PCR (RT-PCR) positive result for SARS-CoV-2
2) Two documented negative RT-PCR results followed by a positive RT-PCR result for SARS-CoV-2
3) Persistently positive RT-PCR for SARS-CoV-2 results for >30 days
Recovery was further defined as occurring at least 10 days after symptom onset and accompanied by resolution of fever for at least 24 hours, without the use of fever-reducing medications, and with improvement of other symptoms [17]. Clinicians and public health personnel could describe patients who met these criteria by completing a brief web-based form on the EIN website. We reviewed entries to assess if cases met potential reinfection criteria and contacted submitters via phone or email for any needed clarifications and to respond to questions.

During May 13, 2020 – June 19, 2020, we included patients for further clinical and laboratory characterization if they met the criteria listed in the EIN post. During June 20, 2020 – July 17, 2020, we narrowed the inclusion criteria to patients with recurrent COVID-19 symptoms [18] and a concurrent positive SARS-CoV-2 RT-PCR result without an alternative diagnosis. We excluded patients who were aged ≤18 years, not meeting the definition of recovery, or without sufficient clinical information to characterize the COVID-19 clinical course.

This investigation was determined to be non-research and was exempt from further institutional review board (IRB) review at CDC, and the University of Iowa IRB determined the investigation to be non-research. This activity was conducted consistent with applicable federal law and CDC policy.  

**Chart Abstraction and Case Review**

For included cases, we requested deidentified medical records pertaining to COVID-19 care and SARS CoV-2 test results (RT-PCR testing laboratory, platform, and cycle threshold [Ct] values; serology). Data on demographics, comorbidities, clinical course, and laboratory testing were abstracted from the medical records and entered into a secured, electronic database (REDCap [Research Electronic Data Capture]) [19]. In addition to data validation checks, three clinician authors reviewed each case to ensure agreement on abstracted data fields, with a focus on SARS-CoV-2 test results and dates of onset and recovery of each clinical episode.

After chart abstraction, three clinician authors classified all patients into four categories based on their clinical course after recovery from an initial episode:

1) Recurrent COVID-19 symptoms without an alternative diagnosis, with concurrent positive SARS-CoV-2 RT-PCR result;
2) Recurrent COVID-19 symptoms with an alternative diagnosis (including potential complications following COVID-19), with concurrent positive SARS-CoV-2 RT-PCR result;
3) Asymptomatic with recurrent positive SARS-CoV-2 RT-PCR after two negative results in specimens collected 24 hours apart;
4) Asymptomatic with recurrent positive SARS-CoV-2 RT-PCR at ≥30 days after recovery, without two negative results in specimens collected 24 hours apart.

**Data Analysis**

We report descriptive statistics to characterize cases according to the four case categories. We expressed continuous variables as medians and interquartile ranges and summarized categorical variables as counts and percentages. All data were analyzed using R software, version 3.6.1 [19].

**Laboratory testing**

We requested available respiratory specimens that tested RT-PCR positive for SARS-CoV-2 from two time points—the initial diagnosis and at the recurrence of COVID-19 symptoms or recurrent test positivity. Respiratory specimens first underwent RT-PCR testing using the SARS-CoV-2 CDC assay

---

1. e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. et seq.
protocol; Ct values were reported for the N1 and N2 viral nucleocapsid protein gene regions (CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel[21]). If the Ct value on the respiratory specimen was ≤34, we attempted: 1) viral culture using Vero-CCL-81 cells; 2) whole genome sequencing (WGS) of extracted nucleic acid [22]; and 3) detection of subgenomic viral RNA transcripts by RT-PCR (i.e., Ct < 40 for both subgenomic spike and nucleocapsid RNA). Specimens also underwent further testing at higher Ct values if laboratory capacity was available. Available serum specimens from after the initial diagnosis were analyzed by chemi-immunoluminescent assay (CIA) to detect total anti-SARS-CoV-2 spike receptor-binding domain. Detailed laboratory methods are described in Supplementary Text 1.

RESULTS

Patient Characteristics

From May 13, 2020, through July 17, 2020, 296 potential cases of reinfection were submitted through the EIN. After initial review, 75 cases did not meet our initial investigation criteria, and another 51 did not meet our narrowed investigation criteria in place after June 19. We requested records for 170 cases and received complete records for 93 cases; upon review of these records, another 20 did not meet investigation criteria (Supplementary Figure 1). In our report, 73 cases were ultimately included. Among these cases, the most common symptoms of the initial COVID-19 episode were respiratory followed by constitutional, and the most common underlying medical condition category was cardiovascular (Table 1).

Of the 73 patients, 49 (67.1%) developed recurrent COVID-19 symptoms after recovery, including 30 patients whose symptoms were explained by an alternative diagnosis, identified either clinically, through laboratory evaluation, or based on treatment response. Of these 30 patients, 8 (26.6%) had cardiac/circulatory (e.g., congestive heart failure leading to shortness of breath) diagnoses at their subsequent episode, 7 (23.3%) had a bacterial infection (e.g., pneumonia improved with antibiotics), 5 (16.7%) had non-infectious pulmonary diagnoses (e.g., asthma exacerbation), 3 (10.0%) had gastrointestinal diagnoses, and 3 (10.0%) had neurological dysfunction; each of the remaining 4 (13.3%) patients had diagnoses related to either autoimmune, endocrine, urological disorders, or fever of unknown origin (Case #24, Table 2). During the recurrent versus initial episode, a lower proportion of patients had respiratory (60.0% vs 90.0%) and constitutional symptoms (40.0% vs 73.3%), and a higher proportion had other symptoms (e.g., headache and chest pain) (70.0% vs 46.7%) (Table 1). The recurrent episode developed a median of 49.5 days (interquartile range [IQR]: 32.3-61.3 days) after the start of the initial episode (Figure 1a).

Nineteen patients had recurrent COVID-19 symptoms unexplained by an alternative diagnosis. Relative to the 30 patients with alternative diagnosis, these 19 patients were younger (median age 32 vs. 63 years), had a higher proportion of healthcare workers (68.4% vs 10.0%), and had fewer underlying conditions (cardiovascular disease 21.1% vs. 73.3%; diabetes 5.3% vs. 53.3%; lung disease 21.1% vs. 36.7%; and immunocompromised 21.1% vs. 36.7%). Further, they were hospitalized less often at both the initial and recurrent COVID-19 episodes (0.0% vs. 56.7%, 5.3% vs. 66.7%, respectively). Their recurrent symptoms developed a median of 57 days after initial symptom onset (IQR: 47 – 76 days; Figure 1b). At the recurrent episode, the majority of patients had respiratory signs and symptoms (16/19 [84.2%]) such as cough and shortness of breath, and constitutional signs and symptoms (14/19 [73.7%]) such as fever and fatigue. One patient required inpatient care, and an additional 13 patients received evaluation at an emergency department, urgent care, or outpatient setting. None of the 19 patients required admission to the intensive care unit or mechanical ventilation at the initial or subsequent episode of illness.
A total of 24 patients displayed no COVID-19 symptoms after recovery. Among 14 patients who remained asymptomatic but had recurrent positive SARS-CoV-2 PCR result after two negatives, 12 (85.7%) were long-term care facility residents tested during routine surveillance or facility contact investigations. These patients received their second negative test a median of 27 days (IQR: 21-33.3) after symptom onset and tested positive again a median of 14 days (IQR: 10.3-19) after receiving their second negative test (Figure 1c). Among the remaining ten asymptomatic patients who remained PCR positive without the intervening two negative results, three were healthcare workers, while others were tested prior to elective medical procedures or as part of a test-based strategy to discontinue isolation. These patients tested positive a median of 56.5 days (IQR: 47.3-66.5) and up to 71 days after their initial symptom onset date (Figure 1d).

**Laboratory Findings**

We received paired specimens from the initial and recurrent COVID-19 symptomatic episodes for nine cases, all of which had tested RT-PCR positive at outside labs under different assays and protocols. Of these, six patients had recurrent COVID-19 symptoms without an alternative diagnosis, and three patients had an alternative diagnosis. Table 2 shows the demographic, clinical presentation, and laboratory test results of these nine cases. All nine initial episode specimens tested positive for SARS CoV-2 on repeat RT-PCR using the CDC assay. Five initial episode specimens underwent additional testing and all were positive for sub-genomic SARS-CoV-2 RNA PCR and viral culture. The remaining four specimens did not undergo additional testing either due to high Ct values (3 cases) or because the specimen had been received prior to the start of our investigation (1 case).

Among nine recurrent episode specimens, repeat RT-PCR at CDC was negative in four specimens and inconclusive for one specimen (Table 2). Among the four specimens with positive RT-PCR results, two specimens had Ct values >34 for N1 and N2 gene targets with viral cultures and whole genome sequencing not attempted or unsuccessful when attempted, and negative sub-genomic RNA PCR. One specimen had a Ct value of 33.0 with negative viral culture, negative sub-genomic RNA PCR, and partial genomic sequencing (<200 base pairs). A fourth specimen had a Ct value of 32.4, and whole genome sequencing was unsuccessful.

Serological specimens were available for four out of nine cases — all were positive for antibodies against SARS-CoV-2 either immediately prior to or at the time of symptom onset for the recurrent episode.

Ct values were reported for an additional 16 cases using a variety of extraction techniques, platforms, and PCR targets applied at the diagnosing labs (Figure 1). Among these cases, only one case (Case 48, Figure 1), a kidney transplant recipient with a complicated medical course, had a value <30 on the subsequent specimen.

**DISCUSSION**

In this investigation of 73 cases of potential SARS-CoV-2 reinfection reported from clinicians across the United States, we did not demonstrate reinfection within 90 days of the initial infection. Clinically, 70% of patients either had recurrent COVID-19 symptoms explained by alternative diagnoses or remained asymptomatic after recovery but were incidentally found to have recurrent or persistent RT-PCR positivity through surveillance and contact investigations. The remaining 19 patients, predominantly healthcare workers, were perhaps more concerning for reinfection because their recurrent COVID-19 symptoms, developing almost two months after recovery, had no alternative diagnoses. Further CDC laboratory investigations of nine available paired specimens from
these cases could not confirm reinfection, with an absence of culturable SARS-CoV-2, sub genomic RNA, or complete genome sequence from the recurrent episode specimen.

Results of paired RT-PCR Ct values for 16 cases, including 12 (of 19) cases most concerning for reinfection demonstrated Ct values >32 from the recurrent episode specimens, suggesting the absence of viable virus. While Ct values are not standardized measures for viral burden, studies performed on diverse specimens, extraction techniques, and platforms found diminishing likelihood of viral isolation with Ct values >30 [3, 23, 24]. While low Ct values raise suspicion for reinfection, the findings of higher Ct values cannot rule-out reinfection but can provide context for the likelihood of replication-competent virus.

Our investigation and previous reports of SARS-CoV-2 reinfection highlight the need for a standardized approach in understanding reinfection. For instance, To, et al. demonstrated SARS-CoV-2 reinfection by showing phylogenetically distinct SARS-CoV-2 viruses from the first and second episodes of infection as well as Ct values and serological findings on the reinfection episode consistent with acute infection [9]. However, additional reports of potential cases of reinfection [24-26] did not present evidence of both distinct viral genomes and significant viral burden on reinfection.

To develop a common understanding of what constitutes reinfection, CDC has issued the Investigative Criteria for Suspected Cases of Reinfection [27], which provides guidance on prioritizing cases with a higher index of suspicion for reinfection and genomic testing of paired specimens, including quality criteria for testing and levels of evidence for reinfection. The highest priority for investigation is suggested for person with detection of SARS-CoV-2 RNA (RT PCR Ct value <33 if known) ≥90 days after the first detection, with or without symptoms, and if paired respiratory specimens are available. For persons with COVID-19–like symptoms and detection of SARS-CoV-2 RNA 45–89 days since first SARS-CoV-2 infection, additional criteria are applied, including absence of an obvious alternative etiology for COVID-19–like symptoms or having had close contact with a person with laboratory-confirmed COVID-19. CDC’s guidance is expected to be updated as evidence regarding the duration and robustness of immunity to SARS-CoV-2 emerge. A Common Investigation Protocol (CIP) [28], has been available to support investigations into suspected SARS-CoV-2 reinfection cases.

This report has several limitations. This investigation was notable for difficulty in obtaining medical and laboratory reports, and specimens for further analysis at CDC, as most laboratories do not routinely retain positive specimens. These challenges contributed to the small sample of cases included in our investigation and tested at CDC. Further, our passive ascertainment of cases through EIN was subject to bias, with an over-representation of healthcare workers or long-term care facility residents, likely reflecting their increased access to SARS-CoV-2 testing. This investigation was focused on potential reinfection cases within 90 days of initial infection, thus we cannot generalize our findings to reinfection beyond 90 days, when waning immunity or divergent strains could increase susceptibility to reinfection.

Re-testing of specimens collected in routine clinical care can have significant variations in specimen collection techniques, timing of repeat testing, and sample degradation that could reduce the likelihood of subsequent WGS, viral culture, and subgenomic RNA, and potentially introduce variability in Ct values. While these issues with retesting of specimens at CDC could have played a role in the failure to culture and sequence recurrent episode specimens (almost all collected within 3
days of symptom onset), our laboratory successfully cultured and sequenced initial episode specimens. Because we did not collect patient identifiers, we were unable to collect exposure and secondary transmission information to support our laboratory findings. Finally, we were unable to rule out reinfection among patients who were asymptomatic with recurrent or persistently positive RT-PCR because we did not receive paired specimens from these cases.

In conclusion, this large public health investigation of potential reinfection contributed to our knowledge of the natural history of SARS-CoV-2 in the United States and informed a standard approach for assessing reinfection. We did not confirm SARS-CoV-2 reinfection within 90 days of the initial infection based on both clinical and laboratory characteristics of 73 cases. Our findings support CDC guidance around quarantine and testing for patients who have recovered from COVID-19 [2]. Additional systematic, prospective cohort investigations [29] are needed to better understand the clinical presentation, risk factors, and frequency of SARS-CoV-2 reinfection cases.
Acknowledgements

We thank the clinicians, infection control staff, and public health staff, who while immersed in caring for their patients and community generously reported information about cases to further our understanding of reinfection. We are especially grateful for the participation of the following individuals: Lilian Abho, Ashley Buys, Matthew Coon, Sherri Davidson, Todd Hulgan, Maria Napierskie, Jennifer Read, Maria Safdar, Alison Wheeler, Pamela Pontones who discussed cases with us, as well as coordinated records and specimens for analysis in this publication; and to CDC CLIA Testing Personnel Lili Punkova and Matthew Pauly. We appreciate Clint Paden and the SPHERES community for their support and helpful discussions. We thank the Emerging Infections Network, especially Susan Beekman for her invaluable support in processing case submissions.

Disclosures

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
REFERENCES

1. World Health Organization. Weekly epidemiological update - 3 Jan 2021 [Internet]. World Health Organization. [cited 2020 Nov 3]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update---5-january-2021

2. Centers for Disease Control and Prevention. Duration of Isolation and Precautions for Adults with COVID-19. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html. Accessed 3 November 2020.

3. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clin Infect Dis 2020;

4. Korean Centers for Disease Control and Prevention. KCDC. 2020. Available at: https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030&act=view&list_no=367267&nPage=1. Accessed 20 June 2020.

5. Liu W-D, Chang S-Y, Wang J-T, et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19. J Infect 2020; Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151379/. Accessed 20 June 2020.

6. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020; 368:860–868.

7. Callow KA, Parry HF, Sergeant M, Tyrrell D a. J. The time course of the immune response to experimental coronavirus infection of man. Epidemiology & Infection 1990; 105:435–446.

8. Kiyuka PK, Agoti CN, Munywoki PK, et al. Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya. J Infect Dis 2018; 217:1728–1739.

9. Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. Nature Medicine 2020; :1–3.

10. Wu L-P, Wang N-C, Chang Y-H, et al. Duration of Antibody Responses after Severe Acute Respiratory Syndrome. Emerg Infect Dis 2007; 13:1562–1564

11. Memish ZA, Perlman S, Kerkhove MDV, Zumla A. Middle East respiratory syndrome. The Lancet 2020; 395:1063–1077.

12. Hoang VT, Dao TL, Gautret P. Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19. Journal of Medical Virology 2020; 92:2366–2367.

13. Van Elslande J, Vermeersch P, Vandervoort K, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis 2020;

14. Yuan J, Kou S, Liang Y, Zeng J, Pan Y, Liu L. Polymerase Chain Reaction Assays Reverted to Positive in 25 Discharged Patients With COVID-19. Clinical Infectious Diseases 2020; 71:2230–2232.

15. Hoang VT, Dao TL, Gautret P. Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19. Journal of Medical Virology 2020; 92:2366–2367.
16. Pillai SK, Beekmann SE, Santibanez S, Polgreen PM. The Infectious Diseases Society of America emerging infections network: bridging the gap between clinical infectious diseases and public health. Clin Infect Dis 2014; 58:991–996.

17. Centers for Disease Control and Prevention. Duration of Isolation and Precautions for Adults with COVID-19 | CDC. 2020. Available at: https://web.archive.org/web/20200718013057/https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html. Accessed 5 September 2020.

18. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) – Symptoms. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed 16 October 2020.

19. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019; 95:103208.

20. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: https://www.R-project.org/. 2020

21. Centers for Disease Control and Prevention. CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. 2020. Available at: https://www.fda.gov/media/134922/download. Accessed 6 September 2020.

22. Paden CR, Tao Y, Queen K, et al. Rapid, Sensitive, Full-Genome Sequencing of Severe Acute Respiratory Syndrome Coronavirus 2. Emerging Infect Dis 2020; 26:2401–2405.

23. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Eurosurveillance 2020; 25:2001483.

24. Abu-Raddad LJ, Chemaitelly H, Malek JA, et al. Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting. Clin Infect Dis 2020;

25. Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. The Lancet Infectious Diseases 2021; 21:52–58.

26. Tomassini S, Kotecha D, Bird PW, Folwell A, Biju S, Tang JW. Setting the criteria for SARS-CoV-2 reinfection – six possible cases. Journal of Infection 2020; :S0163445320305466.

27. Centers for Disease Control and Prevention. Investigative Criteria for Suspected Cases of SARS-CoV-2 Reinfection (ICR). 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html. Accessed 3 November 2020.

28. Centers for Disease Control and Prevention. Common Investigation Protocol for Investigating Suspected SARS-CoV-2 Reinfection. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/php/reinfection.html. Accessed 3 November 2020.

29. Lumley SF, O’Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. New England Journal of Medicine 2020;
Tables and Figures

Table 1. Demographic and Clinical Characteristics of Clinician Suspected Cases of Reinfection

Table 2. Clinical Course and Laboratory Findings of Clinician Suspected Cases of Reinfection with Laboratory Specimens for Testing

Figure 1. Onset of Symptoms and RT-PCR results of Clinician Suspected Cases of Reinfection
Table 1. Demographic and Clinical Characteristics of Potential Cases of Reinfection

| Characteristics                                      | All cases (n = 73) | Cases with recurrent symptoms and positive RT-PCR after recovery (n=49) | Cases who remained asymptomatic with positive RT-PCR after recovery (n=24) |
|------------------------------------------------------|-------------------|-----------------------------------------------------------------------|-------------------------------------------------------------------------|
|                                                      |                   | Recurrent symptoms with alternative diagnosis (n=30)                   | Recurrent symptoms without alternative diagnosis (n=19)                  | Positive RT-PCR after two negative results (n=14) | Positive RT-PCR >30 days after recovery* (n=10) |
| Female sex - no. (%)                                 | 38 (52.1%)        | 13 (43.3%)                                                             | 13 (68.4%)                                                              | 6 (42.9%)                                      | 6 (60.0%)                                     |
| Median age (interquartile range) - yr                | 57.0 (37 - 69)    | 63 (52 - 76)                                                           | 32 (29 - 40)                                                            | 66 (62 - 73)                                   | 46 (37 - 59)                                  |
| Health care worker                                   | 19 (26.0%)        | 3 (10.0%)                                                              | 13 (68.4%)                                                              | 0 (0.0%)                                       | 3 (30.0%)                                     |
| Long term care facility resident                     | 26 (35.6%)        | 14 (46.7%)                                                             | 0 (0.0%)                                                               | 12 (85.7%)                                     | 0 (0.0%)                                      |
| Underlying conditions                                |                   |                                                                      |                                                                        |                                              |                                              |
| Cardiovascular disease - no. (%)                     | 39 (53.4%)        | 22 (73.3%)                                                             | 4 (21.1%)                                                              | 11 (78.6%)                                     | 2 (20.0%)                                     |
| Diabetes - no. (%)                                   | 23 (31.5%)        | 16 (53.3%)                                                             | 1 (5.3%)                                                               | 5 (35.7%)                                      | 1 (10.0%)                                     |
| Lung disease - no. (%)                               | 22 (30.1%)        | 11 (36.7%)                                                             | 4 (21.1%)                                                              | 5 (35.7%)                                      | 2 (20.0%)                                     |
| Immunocompromise - no. (%)                           | 17 (23.3%)        | 11 (36.7%)                                                             | 4 (21.1%)                                                              | 2 (14.3%)                                      | 0 (0.0%)                                      |
| Symptoms present at initial episode                  |                   |                                                                      |                                                                        |                                              |                                              |
| Respiratory - no. (%)                                | 61 (83.6%)        | 27 (90.0%)                                                             | 18 (94.7%)                                                             | 11 (78.6%)                                     | 5 (50.0%)                                     |
| Gastrointestinal - no. (%)                           | 22 (30.1%)        | 8 (26.7%)                                                              | 17 (89.5%)                                                             | 6 (42.9%)                                      | 6 (60.0%)                                     |
| Constitutional - no. (%)                            | 51 (69.9%)        | 22 (73.3%)                                                             | 17 (89.5%)                                                             | 6 (42.9%)                                      | 6 (60.0%)                                     |
| Other - no. (%)                                      | 36 (49.3%)        | 14 (46.7%)                                                             | 15 (78.9%)                                                             | 5 (35.7%)                                      | 2 (20.0%)                                     |
| Symptoms present at subsequent episode               |                   |                                                                      |                                                                        |                                              |                                              |
| Respiratory - no. (%)                                | 34 (69.4%)        | 18 (60.0%)                                                             | 16 (84.2%)                                                             | N/A                                           | N/A                                           |
| Gastrointestinal - no. (%)                           | 16 (32.7%)        | 9 (30.0%)                                                              | 7 (36.8%)                                                              | N/A                                           | N/A                                           |
| Constitutional - no. (%)                            | 26 (53.1%)        | 12 (40.0%)                                                             | 14 (73.7%)                                                             | N/A                                           | N/A                                           |
| Other - no. (%)                                      | 29 (59.2%)        | 21 (70.0%)                                                             | 18 (42.1%)                                                             | N/A                                           | N/A                                           |
| Level of care at initial episode                     |                   |                                                                      |                                                                        |                                              |                                              |
| Inpatient hospital care - no. (%)                    | 25 (34.2%)        | 17 (56.7%)                                                             | 0 (0.0%)                                                               | 7 (50.0%)                                      | 1 (10.0%)                                     |
| Emergency department or urgent care - no. (%)        | 6 (8.2%)          | 2 (6.7%)                                                              | 3 (15.8%)                                                              | 0 (0.0%)                                       | 1 (10.0%)                                     |
| Outpatient care - no. (%)                            | 26 (35.6%)        | 8 (26.7%)                                                              | 8 (42.1%)                                                              | 7 (50.0%)                                      | 3 (30.0%)                                     |
| Self-care - no. (%)                                  | 13 (17.8%)        | 2 (6.7%)                                                              | 7 (36.8%)                                                              | 0 (0.0%)                                       | 4 (40.0%)                                     |
| Missing - no. (%)                                    | 3 (4.1%)          | 1 (3.3%)                                                              | 1 (5.3%)                                                               | 0 (0.0%)                                       | 1 (10.0%)                                     |
| Level of care at subsequent episode                | Inpatient hospital care - no. (%) | Emergency department or urgent Care - no. (%) | Outpatient care - no. (%) | Self-care - no. (%) | Missing - no. (%) |
|--------------------------------------------------|-----------------------------------|----------------------------------------------|---------------------------|---------------------|------------------|
| Inpatient hospital care                          | 21 (42.9%)                       | 20 (66.7%)                                   | 1 (5.3%)                  | N/A                 | N/A              |
| Emergency department or urgent Care              | 8 (16.3%)                        | 5 (26.3%)                                    | 3 (15.8%)                 | N/A                 | N/A              |
| Outpatient care                                   | 13 (26.5%)                       | 3 (10.0%)                                    | 10 (52.6%)                | N/A                 | N/A              |
| Self-care                                        | 5 (10.2%)                        | 1 (3.3%)                                     | 4 (21.1%)                 | N/A                 | N/A              |
| Missing                                          | 2 (4.1%)                         | 1 (3.3%)                                     | 1 (3.3%)                  | N/A                 | N/A              |

**Pattern for Test Results**

| Positive RT-PCR occurring after two negative results | 26 (35.6%) | 11 (36.7%) | 1 (5.3%) | 14 (100.0%) | N/A |
| Positive RT-PCR occurring 30 days after recovery    | 54 (74.0%) | 22 (73.3%) | 14 (73.7%) | 8 (57.1%) | 10 (100.0%) |

*Positive RT-PCR results >30 days after recovery without intervening 2 negative PCR results*
Table 2. Clinical Course and Laboratory Findings of Clinician-Suspected Cases of Reinfection with Laboratory Specimens for Testing

| Case Patient ID | #7 | #9 | #10 | #11 | #15 | #19 |
|----------------|----|----|-----|-----|-----|-----|
| Demographics   | 27M pharmacist, otherwise healthy. | 30F RN with a history of asthma and tachycardia | 61M physician, otherwise healthy | 30F RN with a history of asthma | 25F nursing assistant, otherwise healthy | 37F HCW, with a history of T2DM and psoriasis, not on immunomodulating drugs |
| 1st episode symptom onset to recovery | March 16 – March 30 | March 23 – April 2 | March 11 – March 22 | March 22 – April 02 | April 14 – April 24 | May 03 – May 13 |
| 1st episode primary symptoms | Fevers, cough, sore throat, shortness of breath | Fevers, cough | Fevers, cough, fatigue, rash on back and chest | Fevers, cough, nausea, vomiting, diarrhea, | Fevers, cough, runny nose, change in taste/smell, | Runny nose, change in taste/smell, |
| **Clinical course & treatment** | Outpatient evaluation followed by home care, no steroid or antiviral use | Outpatient evaluation followed by home care, no steroid or antiviral use | Outpatient evaluation followed by home care, no steroid or antiviral use | Outpatient evaluation followed by home care, no steroid or antiviral use | Outpatient evaluation followed by home care, no steroid or antiviral use | Outpatient evaluation followed by home care, no steroid or antiviral use |
| 1st episode specimen tested at CDC (collection date) | NP Swab (March 19) | NP Swab (March 24) | NP Swab (March 12) | NP Swab (March 24) | NP Swab (April 16) | NP Swab (May 03) |
| RT-PCR (N1 Ct) | Positive (19.7) | Positive (27.0) | Positive (18.6) | Positive (17.1) | Positive (16.3) | Positive (30.6) |
| Viral culture* | Not attempted** | Positive | Positive | Positive | Positive | Negative |
| WGS* | Whole genome obtained | Whole genome obtained | Whole genome obtained | Whole genome obtained | Whole genome obtained | Whole genome obtained |
| sgRNA PCR* | Not attempted** | Positive | Positive | Positive | Positive | Negative |
| 2nd episode symptom onset | April 30 | May 07 | April 29 | May 18 | June 12 | July 8 |
| 2nd episode primary symptoms | Fevers, chills, shortness of breath, change in taste/smell, diarrhea | Fever, cough, body aches, diarrhea | Fever | Nausea, diarrhea, myalgia | Fevers, chills, shortness of breath, change in taste/smell, diarrhea | Fevers, fatigue, wheezing |
| 2nd episode specimen tested at CDC (collection date) | NP Swab (May 4) | NP Swab (May 8) | NP Swab (April 29) | NP Swab (May 18) | NP Swab (June 14) | NP Swab (July 8) |
* Respiratory specimens with Ct ≥34 values were not to undergo further testing by protocol but could have been tested if laboratory capacity was available.

**Further testing was not attempted on these specimens pre-existing in the CDC lab before the start of our investigation.

|                      | RT-PCR (N1 Ct) | Viral culture* | WGS* | sgRNA PCR* | SARS-CoV-2 antibody | Additional etiologies identified for recurrent symptoms |
|----------------------|----------------|----------------|------|------------|---------------------|--------------------------------------------------------|
|                      | Positive (32.4)| Not attempted**| Unsuccessful | Not attempted**| No serum available | None |
|                      | Positive (33.0)| Negative       | Partial genome obtained | Negative | Reactive (May 07) | None |
|                      | Positive (37.0)| Not attempted  | Unsuccessful | Not attempted | No serum available | None |
|                      | Inconclusive   | Not attempted  | Unsuccessful | Not attempted | Reactive (May 13) | None |
|                      | Positive (37.7)| Negative       | Unsuccessful | Not attempted | No serum available | None |
|                      | Negative       | Not attempted  | Not attempted | Not attempted | No serum available | None |
Table 2 (cont.). Clinical Course and Laboratory Findings of Clinician Suspected Cases of Reinfection with Laboratory Specimens for Testing

| Case ID | #43 | #30 | #24 |
|---------|-----|-----|-----|
| **Demographics** | 67M LTCF resident with heart failure, chronic kidney disease, bed bound from bilateral above knee amputations from peripheral artery disease | 60F LTCF resident with morbid obesity, asthma, obstructive apnea, and hypertension, chronically bed bound with cerebral palsy | 20F student and part time boat attendant, with a history of morbid obesity, hyperlipidemia, and mood disorders |
| **1st episode symptom onset to recovery** | April 03 – April 21 | April 01 – April 11 | April 15 – April 25 |
| **1st episode primary symptoms** | Fevers, wheezing, hypoxemia | Sore throat, cough, hypoxemia | Cough, runny nose, myalgias, shortness of breath |
| **Clinical course & treatment** | Outpatient care based at LTCF, no steroid or antiviral use | Outpatient care based at LTCF, no steroid or antiviral use | Outpatient evaluation followed by home care, no steroid or antiviral use |
| **1st episode specimen tested at CDC (collection date)** | NP Swab (April 4) | NP Swab (April 7) | NP Swab (April 15) |
| RT-PCR (N1 Ct) | Positive (19.3) | Positive (34.5) | Positive (36.0) |
| Viral culture | Positive | Not attempted | Not attempted |
| WGS | Whole genome obtained | Unsuccessful | Not attempted |
| sgRNA PCR | Positive | Not attempted | Not attempted |
| **2nd episode symptom onset** | June 01 | June 02 | June 12 |
| **2nd episode primary symptoms** | Hypoxemia, shortness of breath, chest tightness | Fevers, sore throat | Fevers, myalgia, change in taste/smell, shortness of breath, nausea/vomiting |
| **2nd episode specimen tested at CDC (collection date)** | NP swab (June 01) | NP Swab (June 02) | NP Swab (June 15) |
| RT-PCR (N1 Ct) | Negative | Negative | Negative |
| Viral culture | Not attempted | Not attempted | Not attempted |
| WGS | Not attempted | Unsuccessful | Not attempted |
| sgRNA PCR | Not attempted | Not attempted | Not attempted |
| **SARS-CoV-2 antibody (collection date)** | Reactive (June 01) | Reactive (June 02) | No serum available |
| **Additional etiologies identified for recurrent symptoms** | Upon evaluation, diagnosed with heart failure exacerbation, symptoms improved after diuresis | Transiently hypoxemic in the context of altered mental status, evaluated briefly at emergency department and returned to LTCF. | Hospitalized and evaluated for fever of unknown origin given prolonged presentation, suspected to have mononucleosis vs Lyme disease. |
